Compare ResMed Inc. (RMD) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Wix.Com Ltd — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Wix.Com Ltd trades at $73.87 (market cap $3.04B). The key difference: ResMed Inc. is far larger — about 10.5× Wix.Com Ltd's market cap, and ResMed Inc. pays a 1.19% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| RMD | WIX | |
|---|---|---|
Market Cap | $31.89B | $3.04B |
Sector | Health | Technology |
52-Week High | $283.28 | $184.24 |
52-Week Low | $182.82 | $40.43 |
Enterprise Value | $31.24B | $4.12B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
WIX trades at $72.72, down 4.58% in the last session, with a bearish technical signal and negative net cash flow of -$344.06M in 2025. Revenue grew to $1.99B in 2025, but net income margin remains negative at -8.19% for 2026. The stock faces multiple class action lawsuits alleging securities fraud, with a deadline of September 22, 2026, adding legal overhangs.
The outlook is mixed: analyst consensus is a Buy with a $73.36 target, near the current price, but risks from litigation and volatile earnings pose headwinds. Investment opportunity hinges on execution amid competitive pressures, while downside protection is limited by weak profitability and negative shareholder equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
